Article

Response of patients with advanced prostatic cancer to administration of somatostatin analog RC-160 (vapreotide) at the time of relapse

Hospital de Especialidades Centro Médico La Raza, IMSS, Departmento Clinico de Endocrinología, Seris y Zaachila, Col. La Raza, Mexico City, D.F. 02990 Mexico.
The Prostate (Impact Factor: 3.57). 08/2003; 56(3):183-91. DOI: 10.1002/pros.10232
Source: PubMed

ABSTRACT The aim of this study was to evaluate the effects of administration of the somatostatin analog RC-160 (vapreotide) at the time of relapse in patients with androgen independent prostate cancer.
Our study included 13 patients with biopsy-proven prostate cancer, stage D3. Eight patients had been treated with a depot formulation of the agonist D-Trp-6-LH-RH, with a median remission time of 68 (range 48-102 months). Five patients were initially treated by surgical orchiectomy, but relapsed after a median time of 33 months (range 17-91 months). A new remission period with a median duration of 10 months (range 2-29 months) was induced with Ketoconazole in the orchiectomy group. At the relapse time, all the patients received 1 mg of vapreotide t.i.d., by subcutaneous route, in addition to D-Trp-6-LH-RH, or Ketoconazole in the orchiectomy group.
Eight of 13 patients demonstrated clinical improvement after 3 months of therapy with vapreotide, six showing a decrease in serum prostate specific antigen (PSA) from 234.5 +/- 308.5 to 68.2 +/- 60.5 ng/ml (mean decline 71 +/- 8%; P < 0.05). Two additional patients presented a fall in serum prostatic acid phosphatase (PAP). Responding patients showed a decrease in the bone pain score from 2.62 +/- 0.48 to 0.37 +/- 0.69 and an increase in the Karnofsky performance status from 72.3 +/- 4.21 to 83.6 +/- 23.2 (P < 0.05). In accord with the ECOG criteria, two patients had a complete response; four had partial response, and two had a stable response. Four patients did not respond and one was not evaluable. Two patients died in remission, one at 16 months due to myocardial infarction and the other at 24 months due to pneumonia. Three patients relapsed at 5, 17, and 19 months respectively. Three patients who have been followed-up for more than 3 years continued in remission (79, 45, and 45 months) respectively. Vapreotide was well tolerated, only three patients having transitory mild diarrhea.
Our results indicate that therapy with the somatostatin analog vapreotide at the time of relapse can induce objective clinical responses in some patients with prostate cancer who are refractory to androgen ablation induced by LH-RH analogs or orchiectomy.

0 Followers
 · 
57 Views
  • Source
    • "Finally, multiple preclinical and clinical investigations are underway to evaluate the potential value of IGF-IR targeting in prostate cancer. GnRH antagonists and somatostatin analogues have been shown to have anti-proliferative eeects in prostate cancer (Dimopoulos et al., 2005; Gonzalez-Barcena et al., 2003). e anti-tumoral activity of these agents in vitro and in vivo was partially attributed to the reduction in GH and IGF-I levels. "
    [Show abstract] [Hide abstract]
    ABSTRACT: The insulin-like growth factor-I receptor (IGF-IR) mediates the biological actions of both IGF-I and IGF-II. The IGF-IR is expressed in most transformed cells, where it displays potent antiapoptotic, cell-survival, and transforming activities. IGF-IR expression is a fundamental prerequisite for the acquisition of a malignant phenotype, as suggested by the finding that IGF-IR-null cells (derived from IGF-IR knock-out embryos) are unable to undergo transformation when exposed to cellular or viral oncogenes. This review article will focus on the underlying molecular mechanisms that are responsible for the normal, physiological control of IGF-IR gene expression, as well as the cellular pathways that underlie its aberrant expression in cancer. Examples from the clinics will be presented, including a description of how the IGF system is involved in breast, prostate, pediatric, and gynecological cancers. Finally, current attempts to target the IGF-IR as a therapeutic approach will be described.
    Archives of Physiology and Biochemistry 06/2009; 115(2):58-71. DOI:10.1080/13813450902783106
  • Source
    • "Finally, multiple preclinical and clinical investigations are underway to evaluate the potential value of IGF-IR targeting in prostate cancer. GnRH antagonists and somatostatin analogues have been shown to have anti-proliferative effects in prostate cancer (Dimopoulos et al., 2005; Gonzalez-Barcena et al., 2003). The anti-tumoral activity of these agents in vitro and in vivo was partially attributed to the reduction in GH and IGF-I levels. "
    [Show abstract] [Hide abstract]
    ABSTRACT: The insulin-like growth factor-I receptor (IGF-IR) mediates the biological actions of both IGF-I and IGF-II. The IGF-IR is expressed in most transformed cells, where it displays potent antiapoptotic, cell-survival, and transforming activities. IGF-IR expression is a fundamental prerequisite for the acquisition of a malignant phenotype, as suggested by the finding that IGF-IR-null cells (derived from IGF-IR knock-out embryos) are unable to undergo transformation when exposed to cellular or viral oncogenes. This review article will focus on the underlying molecular mechanisms that are responsible for the normal, physiological control of IGF-IR gene expression, as well as the cellular pathways that underlie its aberrant expression in cancer. Examples from the clinics will be presented, including a description of how the IGF system is involved in breast, prostate, pediatric, and gynecological cancers. Finally, current attempts to target the IGF-IR as a therapeutic approach will be described.
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Neuroendocrine differentiation in prostatic malignancy is receiving considerable attention; this occurs commonly as a "focal" histological variant and, most rarely, in the form of small cell carcinoma ("oat cell carcinoma") and carcinoid tumor. In prostate cancer, neuroendocrine differentiation may be the response to androgen deprivation and neuroen- docrine products, either biogenic amines or peptides, have been shown to stimulate pro- liferation of androgen-ablation refractory cancer cells. Serum chromogranins, neuron-spe- cific enolase and other neuroendocrine products as well as 111-In-chromogranin A "three step" immunoscintigraphy and somatostatin-receptor scintigraphy may be useful for pre- dicting tumor behaviour and patient prognosis. Several of the neuroendocrine products, particularly somatostatin analogues, are candi- dates for new therapeutic approaches. The paper aims to outline the advances in this field on the basis of the review of the literature. (Urologia 2004; 71: 93-103)
Show more